서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 16 of 16

Issue DateTitle / Author(s) / CitationFileAltmetrics
2009-02
Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer
DOI
2009-07
Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
DOI
2009-11
Incidence and Biologic Features of 5q Deletion and 5q-Syndrome in Myelodysplastic Syndrome in Korea; According to Reclassification of Myelodysplastic Syndrome by WHO 2008.
2010-11
Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML.
2010-11
Bone Marrow Cellularity Is a Single Most Important Independent Prognostic Factor In AML Patients with t(8;21).
2010-12
Cytogenetic features of 5q deletion and 5q-syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization
DOI
2012-06
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research
DOI
2015-08
Phase I/II study of weekly Oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer
DOI
2015-11
Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer
DOI
2018-05
Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
DOI
2019-11
A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
DOI
2020-03
Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia
DOI
2021-06
Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia

Shin, Hyejin; Ha, Jung-Eun; Zang, Dae Young; Kim, Sung-Hyun; Do, Young Rok; Lee, Won Sik; Kim, Dong-Wook; Lee, Jangik, I

Clinical Lymphoma Myeloma & Leukemia, Vol.21 No.6, pp.E521-E529

DOI
2022-01
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
DOI
2022-06
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
DOI
2022-07
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
DOI
1